Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 297 - 304 of 11439 results
LDT Oversight Gets Long-Awaited FDA Final Rule
April 30, 2024| News
PhRMA to Revive Medicare Drug Price Lawsuit Before Fifth Circuit
April 30, 2024| News
What The New Fiduciary Rule Means For Your Retirement Savings
April 30, 2024| News
Industry Fears CERCLA PFAS Rule Will Drive Expanded Five-Year Reviews
April 30, 2024| News
Do Patent Claims to Methods of Treatment Cover In Vivo Transformations?
April 29, 2024| Blog| Viewpoint
ACA Section 1557 Final Rule: OCR Prohibits Discrimination Related to Use of Artificial Intelligence in Health Care
April 29, 2024| Blog| Viewpoint
Telephone and Texting Compliance News — April 2024
April 29, 2024| Article| Viewpoint
News & Press Releases
Venture Mega-Rounds Return to Biotech
September 26, 2024
Member Cheryl Reicin was quoted in WSJ Pro Venture Capital in an article about how venture mega rounds are becoming more frequent in the biotech industry. Specifically, Cheryl discusses the need for startups to be aware of the pressures and implications that may come from larger funding rounds.
Mintz Ranked in 2025 Edition of Chambers Canada
September 26, 2024
Mintz announced that it has been ranked in the 2025 edition of Chambers Canada. The firm was rankedin both the Life Sciences and Cannabis Law categories. Six attorneys were also ranked in individual categories including Life Sciences, Private Equity, Investment Funds, Cannabis, and Pensions & Benefits.
Lenovo’s Setback in Ericsson ITC Case May Impact Other SEP Disputes
September 26, 2024
Intellectual Property Division Chair Michael Renaud was quoted by IAM in an article about the ITC case between Ericsson and Lenovo and its potential implications for FRAND negotiations. While most ITC cases involving Standard Essential Patents (SEPs) have resulted in no violation findings, this case could change that.